Table 1 Baseline sociodemographic and clinical characteristics

Age mean (SD, min-max)

45.6 (10.1, 26–56)

53.3 (9.3, 31–64)

0.019 ^a

Sex f:m

10:1

8:3

0.586^b

BMI mean (SD, min-max)

25.0 (5.0, 20.0–36.9)

28.9 (7.6, 21.6–48.0)

0.116^a

Work status (n)

• Unfit for work (1)

• Retired (3)

• 3-6 h/d (3)

• > 6 h/d (4)

• Unfit for work (1)

• Retired (5)

• 3-6 h/d (3)

• > 6 h/d (2)

0.921^b

MS type RR:SP

9:2

9:2

1.000^b

TSD mean (SD, min-max)

9.5 (7.0, 2–28)

9.7 (8.6, 0–27)

0.699^a

EDSS median (min-max)

3.0 (1.5–4.5)

2.5 (2.0–4.5)

0.748^a

Walking device (n)

0

0

1.000^b

CES-D mean (SD, min-max)

24.7 (11.7, 4–40)

25.7 (8.1, 13–39)

0.818^c

DMT (n)

• None (4)

• Glatiramer acetate (1)

• Natalizumab (1)

• Ofatumumab (1)

• Teriflunomide (1)

• Cladribine (1)

• Fingolimod (1)

• Siponimod (1)

• None (2)

• Glatiramer acetate (2)

• Natalizumab (1)

• Ofatumumab (1)

• Teriflunomide (2)

• Dimethyl fumarate (1)

• Interferone beta-1b (1)

• Ocrelizumab (1)

0.929^b

Fatigue medication (n)

• Amantadine (1)^*

• None (10)

• None (11)

1.000^b